Study to Evaluate OXERVATE® in Patients With Stage 1 Neurotrophic Keratitis

计划入组 37 人 · 首次发布于 2020 年 7 月 24 日

Open-label Trial to Evaluate Efficacy and Safety of rhNGF on Corneal Thickness Via AS-OCT in Neurotrophic Keratitis

计划入组 17 人 · 首次发布于 2024 年 5 月 13 日

Safety and Efficacy Study on Cenegermin (Oxervate®) vs Vehicle in Severe Sjogren's Dry Eye Disease (PROTEGO-1 Study)

计划入组 104 人 · 首次发布于 2021 年 11 月 24 日

Cenegermin(Oxervate)

Rx

X-Synergy®

NanoLithium® NP03

GENOMIC HEALTH, INC.

United States

Theralase Technologies Inc

Canada

Palvella Therapeutics Appoints Rare Disease Commercial Expert Ashley Kline as Chief Commercial Officer

Dompé Receives FDA Priority Voucher for Intranasal NGF Therapy Targeting NAION Vision Loss

ViroGates and Sobi Expand Collaboration on suPARnostic® Diagnostic for Kineret® Treatment